Adjuvant HoldingsLtd Beheer

Beheer criteriumcontroles 2/4

De CEO Adjuvant HoldingsLtd is Yutaka Nakamura, benoemd in Jan2021, heeft een ambtstermijn van 3.83 jaar. bezit rechtstreeks 22.44% van de aandelen van het bedrijf, ter waarde ¥ 1.48B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.6 jaar en 3.4 jaar.

Belangrijke informatie

Yutaka Nakamura

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	3.8yrs
Eigendom CEO	22.4%
Management gemiddelde ambtstermijn	8.6yrs
Gemiddelde ambtstermijn bestuur	3.4yrs

Recente managementupdates

Recent updates

CEO

Yutaka Nakamura (78 yo)

3.8yrs

Tenure

Mr. Yutaka Nakamura has been Chairman of the Board at Adjuvant Cosme Japan Co., Ltd. since June 16, 2016 and serves as President. Mr. Nakamura has been President at K.K.Adjuvant since 1992. Mr. Nakamura E...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Yutaka Nakamura	Chairman & President	3.8yrs	geen gegevens	22.44% ¥ 1.5b
Hideo Nakagawa	GM of Administration & Director	14.1yrs	geen gegevens	0.17% ¥ 11.1m
Takeshi Fujiwara	GM of Sales & Director	3.7yrs	geen gegevens	0.050% ¥ 3.3m
Junko Tanaka	Senior MD & Director	13.3yrs	geen gegevens	15.22% ¥ 1.0b

8.6yrs

Gemiddelde duur

71.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 4929 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yutaka Nakamura	Chairman & President	33.6yrs	geen gegevens	22.44% ¥ 1.5b
Hideo Nakagawa	GM of Administration & Director	13.4yrs	geen gegevens	0.17% ¥ 11.1m
Takeshi Fujiwara	GM of Sales & Director	1.7yrs	geen gegevens	0.050% ¥ 3.3m
Junko Tanaka	Senior MD & Director	no data	geen gegevens	15.22% ¥ 1.0b
Masamitsu Minami	Independent Outside Director	3.4yrs	geen gegevens	0.049% ¥ 3.2m
Junji Mimura	Independent Outside Director	3.4yrs	geen gegevens	0.050% ¥ 3.3m
Kiyoharu Kageta	Independent Outside Director	3.4yrs	geen gegevens	0.025% ¥ 1.6m
Hirokazu Ohshima	Director	1.7yrs	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

71.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4929 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Adjuvant HoldingsLtd Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Adjuvant Holdings Co.,Ltd., Annual General Meeting, Jun 13, 2024

Less than half of directors are independent

Less than half of directors are independent

Adjuvant Holdings Co.,Ltd., Annual General Meeting, Jun 16, 2022

Recent updates

Second quarter 2025 earnings released: EPS: JP¥0.62 (vs JP¥12.13 loss in 2Q 2024)

New major risk - Financial data availability

Adjuvant Holdings Co.,Ltd. to Report Q2, 2025 Results on Oct 18, 2024

First quarter 2025 earnings released: EPS: JP¥1.63 (vs JP¥5.39 loss in 1Q 2024)

Adjuvant Holdings Co.,Ltd. to Report Q1, 2025 Results on Jul 19, 2024

Full year 2024 earnings released: JP¥12.38 loss per share (vs JP¥50.38 profit in FY 2023)

Adjuvant Holdings Co.,Ltd., Annual General Meeting, Jun 13, 2024

Full year 2024 earnings released: JP¥12.38 loss per share (vs JP¥50.38 profit in FY 2023)

Upcoming dividend of JP¥24.00 per share

Adjuvant Holdings Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 19, 2024

Third quarter 2024 earnings released: EPS: JP¥15.50 (vs JP¥15.88 in 3Q 2023)

Adjuvant Holdings Co.,Ltd. to Report Q3, 2024 Results on Jan 19, 2024

Second quarter 2024 earnings released: JP¥12.13 loss per share (vs JP¥1.13 profit in 2Q 2023)

New major risk - Dividend sustainability

New minor risk - Profit margin trend

First quarter 2024 earnings released: JP¥5.39 loss per share (vs JP¥24.74 profit in 1Q 2023)

Full year 2023 earnings released: EPS: JP¥50.38 (vs JP¥49.11 in FY 2022)

Adjuvant Holdings Co.,Ltd. to Report Q2, 2024 Results on Oct 20, 2023

Full year 2023 earnings released: EPS: JP¥50.38 (vs JP¥49.11 in FY 2022)

Upcoming dividend of JP¥24.00 per share at 2.3% yield

Third quarter 2023 earnings released: EPS: JP¥15.88 (vs JP¥19.89 in 3Q 2022)

Adjuvant Holdings Co.,Ltd. to Report Q3, 2023 Results on Jan 20, 2023

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: JP¥1.13 (vs JP¥10.76 in 2Q 2022)

Adjuvant Holdings Co.,Ltd. to Report Q2, 2023 Results on Oct 21, 2022

First quarter 2023 earnings released: EPS: JP¥24.74 (vs JP¥10.76 in 1Q 2022)

Full year 2022 earnings released: EPS: JP¥49.11 (vs JP¥17.78 in FY 2021)

Adjuvant Holdings Co.,Ltd. to Report Q1, 2023 Results on Jul 22, 2022

Less than half of directors are independent

Adjuvant Holdings Co.,Ltd. (TSE:4929) announces an Equity Buyback for 50,000 shares, representing 0.62% for ¥52.5 million.

Adjuvant Holdings Co.,Ltd., Annual General Meeting, Jun 16, 2022

Upcoming dividend of JP¥24.00 per share

Adjuvant Holdings Co.,Ltd. to Report Fiscal Year 2022 Results on Apr 22, 2022

Now 20% undervalued after recent price drop

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: EPS JP¥10.76 (vs JP¥11.14 loss in 2Q 2021)

First quarter 2022 earnings released: EPS JP¥10.76 (vs JP¥0.63 loss in 1Q 2021)

Full year 2021 earnings released: EPS JP¥17.78 (vs JP¥28.51 loss in FY 2020)

Full year 2021 earnings released: EPS JP¥21.79 (vs JP¥28.51 loss in FY 2020)

Upcoming Dividend of JP¥24.00 Per Share

New 90-day high: JP¥1,099

An undisclosed buyer entered into a share transfer agreement to acquire 90% stake in EXCEED system. Co., Ltd., from Adjuvant Cosme Japan Co.,Ltd. (TSE:4929).

New 90-day high: JP¥1,072

Third quarter 2021 earnings released: EPS JP¥24.78

New 90-day high: JP¥1,043

Adjuvant Cosme Japan Co.,Ltd. to Report Q3, 2021 Results on Jan 22, 2021

Adjuvant Cosme Japan Co.,Ltd. to Report Q2, 2021 Results on Oct 23, 2020

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd